OnKure Therapeutics, Inc. (OKUR): Operating Income
-$62.95M
Year ended 2025-12-31
-$62.14M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$62.95M | n/m | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | -$54.39M | n/m | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | -$36.93M | n/m | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | -$53.85M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$39.82M | n/m | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | -$19.55M | n/a | 2022-03-23, From 2020-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | -$62.95M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $6.10M | -50.0% |
| Rallybio Corp (RLYB) | 2025-12-31 | -$33.06M | n/m |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | -$38.11M | n/m |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $16.90M | n/m |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | -$34.40M | n/m |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | -$20.86M | n/m |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | -$18.05M | n/m |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | -$38.60M | n/m |
Compare OKUR, LFVN, RLYB, ANTX side by side · Screen every company in Pharmaceutical Preparations ↗